H. pylori-Associated Gastritis, Gastritis after H. pylori Eradication and H. pylori-Negative Gastritis: Algorithm of Diagnosis and Treatment (Literature Review and Resolution of the Expert Panel of the Russian Gastroenterological Association)

Aim: to provide the basic points of the Expert Panel of the Russian Gastroenterological Association with discussion of measures to improve diagnostics, treatment and management of chronic gastritis patients.

Key points. In the Russian Federation in 2021 more than 30 million patients diagnosed with “Gastritis and duodenitis” were recorded (K29 in accordance with International Classification of Diseases-10). H. pylori incidence rate in the Russian population has reduced and presently is about 40 %. In chronic gastritis pattern H. pylori-associated gastritis has still dominated though gastritis percent after successful H. pylori eradication, reactive gastropathy (including reflux gastritis) and autoimmune gastritis, has increased. Endoscopic and histologic examinations serve as key diagnostic techniques that provide a means for assessing the ethiology of gastritis, topography and degree of atrophic changes, gastritis staging as per OLGA/OLGIM system that properly correlates with the risk of stomach cancer and determines endoscopic examination strategy. H. pylori eradication therapy of gastritis serves as an etiotropic treatment and makes it possible to prevent progression of atrophy and stomach cancer. Conventional triple therapy combined with bismuth tripotassium dicitrate allows for achieving optimal cure rates of H. pylori eradication. Addition of rebamipide to regimens of H. pylori eradication improves their efficiency. Rebamipide arrests symptoms of dyspepsia in the case of chronic gastritis and functional dyspepsia. The administration of rebamipide for chronic gastritis makes it possible to influence the syndrome of increased epithelial permeability and inflammation, which makes it advisable to study it as a means of preventing stomach cancer and the progression of atrophy in various types of chronic gastritis.

Conclusion. Members of the Expert Panel has approved the algorithm of diagnosis and treatment of H. pylori-associated gastritis, gastritis after H. pylori eradication and H. pylori-negative gastritis at the diagnostic stage in the case of initial presentation and long-term follow-up when needed.

1. Kotova E.G., Kobyakova O.S., Aleksandrova G.A., Golubev N.A., Oskov Yu.I., Polikarpov A.V., et al. General morbidity rate of the adult population of Russia in 2021: Statistical materials. Moscow: Central Scientific-Research Institute of Health Organization and Informatization of the Ministry of Health of the Russian Federation, 2022. (In Russ.)].

2. Malfertheiner P., Megraud F., Rokkas T., Gisbert J.P., Liou J.M., Schulz C., et al.; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. DOI: 10.1136/gutjnl-2022-327745

3. Bordin D., Morozov S., Plavnik R., Bakulina N., Voynovan I., Skibo I., et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in Russia: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. DOI: 10.1111/hel.12924

4. Russian Gastroenterological Association, Russian Endoscopic Society, Scientific Society for the Clinical Study of Human Microbiome, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy. Gastritis and duodenitis: Clinical recommendations. Moscow, 2024. (In Russ.)]. URL: https:// cr.minzdrav.gov.ru/recomend/708_2

5. [Ivashkin V.T., Maev I.V., Lapina T.L., Fedorov E.D., Sheptulin A.A., Trukhmanov A.S., et al. Clinical recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on diagnosis and treatment of gastritis and duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70–99. (In Russ.)]. DOI: 10.22416/1382-4376-2021-31-4-70-99

6. Simanenkov V.I., Maev I.V., Tkacheva O.N., Alekseenko S.A., Andreev D.N., Bordin D.S., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.)]. DOI: 10.15829/1728-8800-2021-2758

7. Simanenkov V.I., Maev I.V., Tkacheva O.N., Alekseenko S.A., Andreev D.N., Bakulina N.V., et al. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv. 2022;94(8):940–56. (In Russ.)]. DOI: 10.26442/00403660.2022.08.201523

8. Aleman R.S., Moncada M., Aryana K.J. Leaky gut and the ingredients that help treat it: A review. Molecules. 2023;28(2):619. DOI: 10.3390/molecules28020619

9. Yuan D., Ma Z., Tuo B., Li T., Liu X. Physiological significance of ion transporters and channels in the stomach and pathophysiological relevance in gastric cancer. Evid Based Complement Alternat Med. 2020;2020:2869138. DOI: 10.1155/2020/2869138

10. Suzuki T. Regulation of the intestinal barrier by nutrients: The role of tight junctions. Anim Sci J. 2020;91(1):e13357. DOI: 10.1111/asj.13357

11. Naz A., Obaid A., Awan F.M., Ikram A., Ahmad J., Ali A. Petri net-based model of Helicobacter pylori mediated disruption of tight junction proteins in stomach lining during gastric carcinoma. Front Microbiol. 2017;8:1682. DOI: 10.3389/fmicb.2017.01682

12. Zhang Y., Zhang J., Xia Y., Sun J. Bacterial translocation and barrier dysfunction enhance colonic tumorigenesis. Neoplasia. 2023;35:100847. DOI: 10.1016/j.neo.2022.100847.

13. Khazaaleh S., Alomari M., Rashid M.U., Castaneda D., Castro F.J. Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting. Cleve Clin J Med. 2024;91(1):33–9. DOI: 10.3949/ccjm.91a.23015

14. Lu Y., Jing J., Sun L., Gong Y., Chen M., Wang Z., et al. Expression of claudin-11, -23 in different gastric tissues and its relationship with the risk and prognosis of gastric cancer. PLoS One. 2017;12(3):e0174476. DOI: 10.1371/journal.pone.0174476

15. Bakulina N.V., Tikhonov S.V., Okovityi S.V., Lutaenko E.А., Bolshakov A.O., Prikhodko V.A., et al. Pharmacokinetics and pharmacodynamics of rebamipide. New possibilities of therapy: A review. Terapevticheskii Arkhiv. 2022;94(12):1431–7. (In Russ.)]. DOI: 10.26442/00403660.2022.12.202000

16. Andreev D.N., Maev I.V., Bordin D.S., Lyamina S.V., Dicheva D.T., Fomenko A.K., et al. Effectiveness of Rebamipide as a part of the Helicobacter pylori eradication therapy in Russia: A meta-analysis of controlled trials. Consilium Medicum. 2022;24(5): 333–8. (In Russ.)]. DOI: 10.26442/20751753.2022.5.201863

17. Seo G.H., Lee H. Chemopreventive effect of rebamipide against gastric cancer in patients who undergo endoscopic resection for early gastric neoplasms: A nationwide claims study. Digestion. 2019;100(4):221–8. DOI: 10.1159/000495288

18. Lapina T.L., Ivashkin V.T. Rebamipide during chronic gastritis: H. pylori eradication therapy and restoration of gastric mucosa barrier function. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(6):81–7. (In Russ.)]. DOI: 10.22416/1382-4376-2023-33-6-81-87

19. Jaafar M.H., Safi S.Z., Tan M.P., Rampal S., Mahadeva S. Efficacy of rebamipide in organic and functional dyspepsia: A systematic review and meta-analysis. Dig Dis Sci. 2018;63(5):1250–60. DOI: 10.1007/s10620-017-4871-9

20. Bakulina N.V., Oganesova I.A., Topalova Y.G., Bakulin I.G. Gastritis and dyspepsia: 2 names of one problem? Relations between predominant symptom and syndromal characteristics of upper GI disorders: Results of a survey of physicians. Medical Council. 2021;(15):30–9. (In Russ.)]. DOI: 10.21518/2079-701X-2021-15-30-39

21. Ford A.C., Tsipotis E., Yuan Y., Leontiadis G.I., Moayyedi P. Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: Updated systematic review and meta-analysis. Gut. 2022:gutjnl-2021-326583. DOI: 10.1136/gutjnl-2021-326583

22. Talley N.J. Functional dyspepsia: New insights into pathogenesis and therapy. Korean J Intern Med. 2016;31(3):444–56. DOI: 10.3904/kjim.2016.091

23. Kucheryavyy Yu.A., Andreev D.N., Maev I.V. Prevalence of small bowel bacterial overgrowth in patients with functional dyspepsia: A meta-analysis. Terapevticheskii Arkhiv. 2020;92(12):53–8. (In Russ.)]. DOI: 10.26442/00403660.2020.12.200433

24. Jung S.W., Joo M.S., Choi H.C., Jang S.I., Woo Y.S., Kim J.B., et al. Epigastric symptoms of gallbladder dyskinesia mistaken for functional dyspepsia: Retrospective observational study. Medicine (Baltimore). 2017;96(16):e6702. DOI: 10.1097/MD.0000000000006702

25. Lake A., Rao S.S.C., Larion S., Spartz H., Kavuri S. Bile reflux gastropathy and functional dyspepsia. J Neurogastroenterol Motil. 2021;27(3):400–7. DOI: 10.5056/jnm20102

26. Kucheryavyy Y.A., Andreev D.N., Andreev N.G. The role of bile acids in the pathogenesis of functional dyspepsia: An unfilled therapeutic niche. Consilium Medicum. 2020;22(8):46–50. (In Russ.)]. DOI: 10.26442/20751753.2020.8.200400

27. Igarashi M., Nakae H., Matsuoka T., Takahashi S., Hisada T., Tomita J., et al. Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia. BMJ Open Gastroenterol. 2017;4(1):e000144. DOI: 10.1136/bmjgast-2017-000144

28. Kim B.T., Kim K.M., Kim K.N. The effect of ursodeoxycholic acid on small intestinal bacterial overgrowth in patients with functional dyspepsia: A pilot randomized controlled trial. Nutrients. 2020;12(5):1410. DOI: 10.3390/nu12051410

29. Mao Q., Lin B., Zhang W., Zhang Y., Zhang Y., Cao Q., et al. Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: Current evidence and perspectives. Front Pharmacol. 2024;15:1371574. DOI: 10.3389/fphar.2024.1371574

30. Tsapkova L.A., Polyakova V.V., Bodunova N.A., Baratova I.V., Voynovan I.N., Dekhnich N.N., et al. Possibilities of the molecular genetic method for detecting resistance to clarithromycin and levofloxacin in Helicobacter pylori. Effective Pharmacotherapy. 2022;18(42):16–21. (In Russ.)]. DOI: 10.33978/23073586-2022-18-42-16-21

31. Nyssen O.P., Vaira D., Tepes B., Kupcinskas L., Bordin D., Pérez-Aisa Á., et al. Room for improvement in the treatment of Helicobacter pylori infection: Lessons from the European Registry on H. pylori management (Hp-EuReg). J Clin Gastroenterol. 2022;56(2):e98–108. DOI: 10.1097/MCG.0000000000001482

32. McNicholl A.G., Bordin D.S., Lucendo A., Fadeenko G., Fernandez M.C., Voynovan I., et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90 % of patients. Clin Gastroenterol Hepatol. 2020;18(1):89–98. DOI: 10.1016/j.cgh.2019.03.048

33. Nishizawa T., Nishizawa Y., Yahagi N., Kanai T., Takahashi M., Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(Suppl 4):20–4. DOI: 10.1111/jgh.12769

34. Andreev D.N., Maev I.V., Dicheva D.T. Efficiency of the inclusion of rebamipide in the eradication therapy for Helicobacter pylori infection: Meta-analysis of randomized controlled studies. J Clin Med. 2019;8(9):1498. DOI: 10.3390/jcm8091498

35. Bordin D.S., Abdulkhakov S.R., Andreev D.N., Voynovan I.N., Bakulin I.G., Bakulina N.V., et al. Effectiveness of rebamipide-containing first-line empirical eradication therapy in Russia: Results from the European Registry on Helicobacter pylori management (Hp-EuReg). Microb Health Dis. 2024; In press.

36. Rugge M., Correa P., Dixon M.F., Fiocca R., Hattori T., Lechago J., et al. Gastric mucosal atrophy: Interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002;16(7):1249–59. DOI: 10.1046/j.1365-2036.2002.01301.x

37. Rugge M., Genta R.M., Malfertheiner P., Dinis-Ribeiro M., El-Serag H., Graham D.Y., et al.; RE.GA.IN; RE GA IN. RE.GA.IN.: The Real-world Gastritis Initiative — updating the updates. Gut. 2024;73(3):407–41. DOI: 10.1136/gutjnl-2023-331164

38. Tertychnyy А.S., Lapina Т.L., Nagornaya D.Р., Pachuashvili N.V., Kiryukhin А.Р., Fedorenko А.А., et al. Spectrum of chronic gastritis based on morphological examination of gastric biopsies. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):45–56. (In Russ.)]. DOI: 10.22416/13824376-2024-34-2-45-56

39. Bordin D.S., Kuznetsova E.S., Stauver E.E., Nikol'skaya K.A., Chebotareva M.V., Voynovan I.N., et al. Epidemiology of Helicobacter pylori infection in the Russian Federation from 1990 to 2023: A systematic review. Russian Medical Inquiry. 2024;8(5):260–7. (In Russ.)]. DOI: 10.32364/2587-6821-2024-8-5-3

40. Sugano K., Tack J., Kuipers E.J., Graham D.Y., ElOmar E.M., Miura S., et al.; Faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67. DOI: 10.1136/gutjnl-2015-309252

41. Haruma K., Kato M., Inoue K., Murakami K., Kamada T. Kyoto classification of Gastritis. 1st ed. Tokyo Japan: Nihon Medical Center, 2017.

42. Toyoshima O., Nishizawa T., Yoshida S., Sakaguchi Y., Nakai Y., Watanabe H., et al. Endoscopy-based Kyoto classification score of gastritis related to pathological topography of neutrophil activity. World J Gastroenterol. 2020;26(34):5146–55. DOI: 10.3748/wjg.v26.i34.5146

43. Tahara T., Shibata T., Nakamura M., Yoshioka D., Okubo M., Arisawa T., et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc. 2009;70(2):246–53. DOI: 10.1016/j.gie.2008.11.046

44. Yagi K., Nakamura A., Sekine A. Characteristic endoscopic and magnified endoscopic findings in the normal stomach without Helicobacter pylori infection. J Gastroenterol Hepatol. 2002;17(1):39–45. DOI: 10.1046/j.1440-1746.2002.02665.x

45. Bordin D.S., Livzan M.A., Gaus O.V., Mozgovoi S.I., Lanas A. Drug-associated gastropathy: Diagnostic criteria. Diagnostics (Basel). 2023;13(13):2220. DOI: 10.3390/diagnostics13132220

46. Nel W. Gastritis and gastropathy: More than meets the eye. Continuing Medical Education. 2013;31(2):37–40.

47. Livzan M.A., Gaus O.V., Mozgovoi S.I., Telyatnikova L.I. Biliary gastritis: Modern methods of diagnosis and therapy. Russian Medical Inquiry. 2022;6(5):244–51. (In Russ.)]. DOI: 10.32364/2587-68212022-6-5-244-251

48. Meshkinpour H., Orlando R.A., Arguello J.F., DeMicco M.P. Significance of endoscopically visible blood vessels as an index of atrophic gastritis. Am J Gastroenterol. 1979;71(4):376–9.

49. Kato M., Uedo N., Toth E., Shichijo S., Maekawa A., Kanesaka T., et al. Differences in image-enhanced endoscopic findings between Helicobacter pylori-associated and autoimmune gastritis. Endosc Int Open. 2021;9(1):E22–30. DOI: 10.1055/a-1287-9767

50. Drapkina O.M., Kashin S.V., Kuvaev R.O., Kaibysheva V.O., Krainova E.A., Shepel R.N., et al. Modern algorithm of diagnostics and management of patients with chronic atrophic gastritis and intestinal metaplasia of the stomach. Russian Journal of Preventive Medicine. 2023;26(1):7–10. (In Russ.)]. DOI: 10.17116/profmed2023260117

51. Kimura K., Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(3):87–97. DOI: 10.1055/s-0028-1098086

52. Terao S., Suzuki S., Yaita H., Kurahara K., Shunto J., Furuta T., et al. Multicenter study of autoimmune gastritis in Japan: Clinical and endoscopic characteristics. Dig Endosc. 2020;32(3):364–72. DOI: 10.1111/den.13500

53. Kuvaev R., Kashin S., Kraynova E. А new indicator for autoimmune gastritis by magnifying image-enhanced endoscopy: “Glomus-like” lesions of the gastric corpus. Dig Endosc. 2022;34(Suppl 1):52. DOI: 10.1111/den.14291

54. Kiryukhin A.P., Tertychnyy A.S., Pavlov P.V., Fedorenko A.A., Nagornaya D.P., Marenich N.S., et al. Autoimmune gastritis: Focus on endoscopic and morphological characteristics. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(1):58–69. (In Russ.)]. DOI: 10.22416/1382-43762024-34-1-58-69

55. Kishino M., Nonaka K. Endoscopic features of autoimmune gastritis: Focus on typical images and early images. J Clin Med. 2022;11(12):3523. DOI: 10.3390/jcm11123523

56. Kaminishi M., Yamaguchi H., Nomura S., Oohara T., Sakai S., Fukutomi H., et al. Endoscopic classification of chronic gastritis based on a pilot study by the research society for gastritis. Dig Endosc. 2002;14(4):138–51. DOI: 10.1046/j.1443-1661.2002.00199.x

57. Nagata N., Shimbo T., Akiyama J., Nakashima R., Kim H.H., Yoshida T., et al. Predictability of gastric intestinal metaplasia by mottled patchy erythema seen on endoscopy. Gastroenterology Res. 2011;4(5):203–9. DOI: 10.4021/gr357w

58. Uedo N., Ishihara R., Iishi H., Yamamoto S., Yamamoto S., Yamada T., et al. A new method of diagnosing gastric intestinal metaplasia: Narrow-band imaging with magnifying endoscopy. Endoscopy. 2006;38(8):819–24. DOI: 10.1055/s-2006-944632

59. Yao K., Iwashita A., Nambu M., Tanabe H., Nagahama T., Maki S., et al. Nature of white opaque substance in gastric epithelial neoplasia as visualized by magnifying endoscopy with narrow-band imaging. Dig Endosc. 2012;24(6):419–25. DOI: 10.1111/j.1443-1661.2012.01314.x

60. McCabe M.E. 4th, Dilly C.K. New causes for the old problem of bile reflux gastritis. Clin Gastroenterol Hepatol. 2018;16(9):1389–92. DOI: 10.1016/j.cgh.2018.02.034

61. Livzan M.A., Mozgovoi S.I., Gaus O.V., Bordin D.S., Kononov A.V. Diagnostic principles for chronic gastritis associated with duodenogastric reflux. Diagnostics (Basel). 2023;13(2):186. DOI: 10.3390/diagnostics13020186

62. Desipio J., Friedenberg F.K., Korimilli A., Richter J.E., Parkman H.P., Fisher R.S. High-resolution solid-state manometry of the antropyloroduodenal region. Neurogastroenterol Motil. 2007;19(3):188–95. DOI: 10.1111/j.1365-2982.2006.00866.x

63. Indireshkumar K., Brasseur J.G., Faas H., Hebbard G.S., Kunz P., Dent J., et al. Relative contributions of “pressure pump” and “peristaltic pump” to gastric emptying. Am J Physiol Gastrointest Liver Physiol. 2000;278(4):G604–16. DOI: 10.1152/ajpgi.2000.278.4.G604

64. Camilleri M., Bharucha A.E., di Lorenzo C., Hasler W.L., Prather C.M., Rao S.S., et al. American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol Motil. 2008;20(12):1269–82. DOI: 10.1111/j.13652982.2008.01230.x

65. Sheptulin A.A., Storonova O.A., Pavlov P.V., Tertychny A.S., Protsenko D.D., Feoktistova K.V. Biliary reflux gastritis: Features of pathogenesis, diagnostics and treatment. Klinicheskaya meditsina. 2023;101(7–8):404–9. (In Russ.)]. DOI: 10.30629/0023-2149-2023-101-7-8-404-409

66. Vere C.C., Cazacu S., Comănescu V., Mogoantă L., Rogoveanu I., Ciurea T. Endoscopical and histological features in bile reflux gastritis. Rom J Morphol. 2005;46(4):269–74.

67. Lemeshko Z.A., Osmanova Z.M. Ultrasound diagnostics of gastric diseases: A guide. 2nd edition, revised and corrected. Moscow: GEOTAR-Media, 2021. (In Russ.)]. DOI: 10.33029/97045944-7-USD-2021-1-88

68. Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Clinical impact of 24-hour pH-metry in esophageal and stomach diseases diagnostics and pharmacological drugs efficacy testing. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(6):55–68. (In Russ.)]. DOI: 10.22416/1382-4376-2016-6-55-68

69. Storonova O.A., Trukhmanov A.S. A Manual for the practicing physician: About prolonged intragastric pH-metry. 2nd edition, ed. By V.T. Ivashkin. Moscow, 2015. (In Russ.)].

70. He Q., Liu L., Wei J., Jiang J., Rong Z., Chen X., et al. Roles and action mechanisms of bile acid-induced gastric intestinal metaplasia: A review. Cell Death Discov. 2022;8(1):158. DOI: 10.1038/s41420-022-00962-1

71. Lei X., Cui Z.Y., Huang X.J. Exploration of gastric carcinogenesis from the relationship between bile acids and intestinal metaplasia and intragastric microorganisms (H. pylori and non-H. pylori). J Cancer Res Clin Oncol. 2023;149(18):16947–56. DOI: 10.1007/s00432-023-05407-5

72. [Livzan M.A., Mozgovoy S.I., Kononov A.V. Gastritis after eradication of Helicobacter pylori — simple traces or serious consequences? Lechashchii Vrach. 2011;7:14– 31. (In Russ.)].

73. Kononov A.V., Mozgovoy S.I., Livzan M.A., Predvechnaia I.K., Novikova L.D. Morphology of surface and atrophic gastritis in eradication of Helicobacter pylori (HP)]. Russian Journal of Archive of Pathology. 2005;67(3):17–21. (In Russ.)].

74. Haruma K., Ito M., Kido S., Manabe N., Kitadai Y., Sumii M., et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862–7. DOI: 10.1023/a:1014716822702

75. Kamada T., Sato M., Tokutomi T., Watanabe T., Murao T., Matsumoto H., et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: A multicenter study. Biomed Res Int. 2015;2015:865146. DOI: 10.1155/2015/865146

76. Han X., Jiang K., Wang B., Zhou L., Chen X., Li S. Effect of rebamipide on the premalignant progression of chronic gastritis: A randomized controlled study. Clin Drug Investig. 2015;35(10):665–73. DOI: 10.1007/s40261-015-0329-z

77. Lee J.S., Jeon S.W., Lee H.S., Kwon Y.H., Nam S.Y., Bae H.I., et al. Rebamipide for the improvement of gastric atrophy and intestinal metaplasia: A prospective, randomized, pilot study. Dig Dis Sci. 2022;67(6):2395–402. DOI: 10.1007/s10620-021-07038-7

78. Losik E.A. Clinical and morphological characteristics of autoimmune gastritis: Thesis of Cand. Sci. (Med.). Moscow, 2018. (In Russ.)].

79. Bakulina N., Tikhonov S., Malkov V., Vorobyev S., Belyakov I., Peshkova N., et al. Non-invasive screening of autoimmune atrophic gastritis in asymptomatic subjects by serological biomarker test (GastroPanel®). Anticancer Res. 2022;42(3):1517–26. DOI: 10.21873/anticanres.15624

80. Tertychnyy A.S., Pachuashvili N.V., Nagornaya D.P., Lapina T.L., Losik E.A., Ponomarev A.B., et al. Clinical and morphological features of dysplasia and early gastric cancer in the patients with autoimmune gastritis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(3):16–33. (In Russ.)]. DOI: 10.22416/1382-4376-2023-33-3-16-33

81. Dilaghi E., Dottori L., Pivetta G., Dalla Bella M., Esposito G., Ligato I., et al. Incidence and predictors of gastric neoplastic lesions in corpus-restricted atrophic gastritis: A single-center cohort study. Am J Gastroenterol. 2023;118(12):2157–65. DOI: 10.14309/ajg.0000000000002327

82. Chen C., Yang Y., Li P., Hu H. Incidence of gastric neoplasms arising from autoimmune metaplastic atrophic gastritis: A systematic review and case reports. J Clin Med. 2023;12(3):1062. DOI: 10.3390/jcm12031062

83. Murphy J.D., Gadalla S.M., Anderson L.A., Rabkin C.S., Cardwell C.R., Song M., et al. Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom. Br J Cancer. 2024;131(1):138–48. DOI: 10.1038/s41416-024-02714-7

84. Rugge M., Bricca L., Guzzinati S., Sacchi D., Pizzi M., Savarino E., et al. Autoimmune gastritis: Long-term natural history in naive ̈ Helicobacter pylori-negative patients. Gut. 2023;72(1):30–8. DOI: 10.1136/gutjnl-2022-327827

85. Livzan M.A., Gaus O.V., Mozgovoi S.I., Bordin D.S. Chronic autoimmune gastritis: Modern diagnostic principles. Diagnostics (Basel). 2021;11(11):2113. DOI: 10.3390/diagnostics11112113